News | May 28, 2007

Study to Probe Adoption Variables in Atrial Fibrillation Therapy

May 29, 2007 — Frost & Sullivan is launching a new end user study on the state of adoption for atrial fibrillation therapies in the U.S. cardiovascular market. Through more than 150 detailed interviews with electrophysiologists, cardiologists and other cardiovascular professionals, the company aims to elucidate key drivers and obstacles to adoption and utilization of various atrial fibrillation treatments.

"Currently no ablation system to date has been approved explicitly for use in treating atrial fibrillation," notes Frost & Sullivan Industry Analyst Venkat Rajan. "However, advancements in 3-D mapping, other imaging techniques, and features within the systems themselves are enabling higher success rates for procedures. Thereby expanding confidence among end users, and gathering enough clinical data for possible FDA approval."

While there are numerous medical device therapies that are being used to treat atrial fibrillation, such as minimally invasive surgical ablation, catheter ablation, open heart surgery ablation, pacemakers, anticoagulants, etc., physician awareness and preference are often the primary determinants of the method used.

"There are a vast number of participants in the market from start-ups and entrepreneurial-type companies to nearly every major cardiovascular device manufacturer," explains Rajan. "Each manufacturer seems to be attempting to carve out their own niche in the market, whether it is through energy modality, or navigational capabilities."

"Manufacturers that can better understand the drivers and obstacles of adoption and utilization preferences for atrial fibrillation device therapies can develop and refine their technologies to best serve customer demand," says Rajan. "With effective third party information partners, companies can take steps to ensure their continued success."

For more information, visit www.frost.com.

Related Content

The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab| July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Cardiologs ECG Analysis Platform Receives FDA Clearance
Technology | ECG Monitoring Services| July 13, 2017
Cardiologs Technologies SAS announced that it has received U.S. Food and Drug Administration (FDA) clearance of its...
Overlay Init